Studies from Zhengzhou University Reveal New Findings on Nanovesicles (Platelet Membrane-camouflaged Nanovesicle Targeted Delivery of Mln4924 for Antitumor Therapy).

Researchers from Zhengzhou University in China have developed a biomimetic nanovesicle platform called P-PAM/MLN for targeted delivery of the anticancer drug MLN4924. This platform utilizes platelet membrane vesicles to enhance tumor affinity and reduce off-target toxicity. The nanovesicles selectively release the drug in response to the acidic microenvironment of lysosomal compartments, effectively inhibiting tumor progression with minimal toxicity. This study provides a promising approach for delivering small molecule drugs to tumor tissues and offers insights for combining nanocarriers with clinical drugs. [Extracted from the article]